<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621047</url>
  </required_header>
  <id_info>
    <org_study_id>NP29783</org_study_id>
    <secondary_id>2015-002976-25</secondary_id>
    <nct_id>NCT02621047</nct_id>
  </id_info>
  <brief_title>Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib</brief_title>
  <official_title>The Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib: A Multiple-Center, Open-Label Study Following Single Oral Dosing of Alectinib to Subjects With Hepatic Impairment and Matched Healthy Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a multicenter, non-randomized, single-dose, open-label study conducted in male and
      surgically sterile or post-menopausal female participants with stable chronic hepatic
      impairment and in healthy participants matched by age, gender, and body weight to assess the
      effect of hepatic impairment on the pharmacokinetics of alectinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2015</start_date>
  <completion_date type="Actual">December 8, 2016</completion_date>
  <primary_completion_date type="Actual">December 8, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Total Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Unbound Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC 0-inf) for Total Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. AUC 0-inf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-inf for Unbound Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measureable Concentration (AUC 0-last) for Total Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-last for Unbound Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Total Metabolite of Alectinib (M4)</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total M4 = unbound M4 plus M4 bound to plasma proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Unbound M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Total Combined Alectinib and M4 (Alectinib + M4)</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib + M4 = unbound alectinib + M4 plus alectinib + M4 bound to plasma proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Unbound Alectinib + M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-inf of Total M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total M4 = unbound M4 plus M4 bound to plasma proteins. AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-inf of Unbound M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-inf of Total Alectinib + M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib + M4 = unbound alectinib + M4 plus alectinib + M4 bound to plasma proteins. AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-inf of Unbound Alectinib + M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-last of Total M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total M4 = unbound M4 plus M4 bound to plasma proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-last of Unbound M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-last of Total Alectinib + M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib + M4 = unbound alectinib + M4 plus alectinib + M4 bound to plasma proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-last of Unbound Alectinib + M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for Total M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total M4 = unbound M4 plus M4 bound to plasma proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of Total Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. t1/2 = the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Total M4</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total M4 = unbound M4 plus M4 bound to plasma proteins. t1/2 = the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Total Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. Clearance is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Unbound Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Clearance is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for Total Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. Volume of distribution is defined as the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F for Unbound Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Volume of distribution is defined as the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Drug Unbound (fu) of Total Alectinib</measure>
    <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
    <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. fu = ratio of unbound alectinib to total alectinib multiplied by 100.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Alectinib: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alectinib: Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 mg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alectinib: Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal hepatic function will receive alectinib at a single oral dose of 300 mg on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Participants will receive alectinib as per the dosage schedule mentioned in arm description.</description>
    <arm_group_label>Alectinib: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Alectinib: Normal Hepatic Function</arm_group_label>
    <arm_group_label>Alectinib: Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Participants

          -  Body mass index between 18 to 35 kilograms per square meter (kg/m^2) inclusive and
             weight greater than (&gt;) 50 kilograms (kg)

          -  Female participants must be surgically sterile or post-menopausal

          -  Male participants and their partners of child-bearing potential must be willing to use
             2 effective methods of contraception, one of which must be a barrier method

        Participants with Hepatic Impairment

        - Documented chronic stable liver disease (Child-Pugh Class A, B or C)

        Exclusion Criteria:

        All Participants

          -  Pregnant or lactating women, males with female partners who are pregnant or lactating,
             or women of child bearing potential

          -  Positive test for drugs of abuse or alcohol

          -  Participation in an investigational drug or device study within 45 days or 5
             half-lives (whichever time period is longer) or 6 months for biologic therapies prior
             to study drug administration

          -  History of hypersensitivity to any of the additives in the alectinib formulation

          -  Participants under judicial supervision, guardianship, or curatorship

          -  History of severe drug-related allergic reactions or drug-induced hepatotoxicity

        Healthy Participants

          -  Use of any medications (prescription or over-the-counter), within 2 weeks or 5
             half-lives (whichever longer) prior to study drug administration

          -  Use of any herbal supplements or any metabolic inducers within 4 weeks, or 5
             half-lives (whichever is longer) prior to study drug administration

        Participants with Hepatic Impairment

          -  Positive screening test for human immunodeficiency virus (HIV)

          -  History of liver transplantation

          -  Hepatocellular carcinoma or acute liver disease

          -  Severe ascites at screening or admission to the clinic

          -  Recent history (past 2 years) or current severe hepatic encephalopathy (Grade 3 or
             higher)

          -  Any evidence of progressive liver disease within the last 4 weeks

          -  Presence of surgically created or transjugular intrahepatic portal systemic shunts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates CZ, s.r.o.</name>
      <address>
        <city>Praha 7</city>
        <zip>170 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research s.r.o.; Oddelenie internej mediciny a klinickej farmakologie</name>
      <address>
        <city>Bratislava</city>
        <zip>831 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <results_first_submitted>November 7, 2017</results_first_submitted>
  <results_first_submitted_qc>November 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2018</results_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer</keyword>
  <keyword>Alectinib</keyword>
  <keyword>Hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>‘Alectinib: Normal Hepatic Function’ participants were grouped into 2 arms: ‘Alectinib: Normal Moderate Matched Control’ and ‘Alectinib: Normal Severe Matched Control’. Same ‘Alectinib: Normal Hepatic Function’ participant could be included in both ‘Alectinib: Normal Moderate Matched Control’ and ‘Alectinib: Normal Severe Matched Control’ arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alectinib: Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Alectinib: Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Alectinib: Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received alectinib at a single oral dose of 300 mg on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who were enrolled in the study and received study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Alectinib: Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Alectinib: Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Alectinib: Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received alectinib at a single oral dose of 300 mg on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="8.52"/>
                    <measurement group_id="B2" value="53.1" spread="5.62"/>
                    <measurement group_id="B3" value="52.2" spread="7.98"/>
                    <measurement group_id="B4" value="53.1" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Total Alectinib</title>
        <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population included all participants who were enrolled in the study, received study treatment, and had pharmacokinetic data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Total Alectinib</title>
          <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins</description>
          <population>Pharmacokinetic population included all participants who were enrolled in the study, received study treatment, and had pharmacokinetic data available.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="35.9"/>
                    <measurement group_id="O2" value="83.6" spread="58.4"/>
                    <measurement group_id="O3" value="85.5" spread="54.4"/>
                    <measurement group_id="O4" value="85.1" spread="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio Percentage (%)</param_type>
            <param_value>128</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.5</ci_lower_limit>
            <ci_upper_limit>188</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>100</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.1</ci_lower_limit>
            <ci_upper_limit>183</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Unbound Alectinib</title>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Unbound Alectinib</title>
          <population>Pharmacokinetic population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="35.3"/>
                    <measurement group_id="O2" value="16.2" spread="38.7"/>
                    <measurement group_id="O3" value="16.1" spread="33.1"/>
                    <measurement group_id="O4" value="12.3" spread="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>148</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>106</ci_lower_limit>
            <ci_upper_limit>208</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>130</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75.4</ci_lower_limit>
            <ci_upper_limit>225</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC 0-inf) for Total Alectinib</title>
        <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. AUC 0-inf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC 0-inf) for Total Alectinib</title>
          <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. AUC 0-inf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
          <population>Pharmacokinetic population</population>
          <units>hour*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2920" spread="60.5"/>
                    <measurement group_id="O2" value="1830" spread="40.4"/>
                    <measurement group_id="O3" value="3850" spread="54.1"/>
                    <measurement group_id="O4" value="1750" spread="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>160</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>105</ci_lower_limit>
            <ci_upper_limit>243</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>220</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>131</ci_lower_limit>
            <ci_upper_limit>369</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0-inf for Unbound Alectinib</title>
        <description>AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-inf for Unbound Alectinib</title>
          <description>AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
          <population>Pharmacokinetic population</population>
          <units>hour*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="659" spread="60.5"/>
                    <measurement group_id="O2" value="355" spread="27.4"/>
                    <measurement group_id="O3" value="725" spread="37.8"/>
                    <measurement group_id="O4" value="254" spread="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>186</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>122</ci_lower_limit>
            <ci_upper_limit>281</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>285</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>175</ci_lower_limit>
            <ci_upper_limit>466</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measureable Concentration (AUC 0-last) for Total Alectinib</title>
        <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measureable Concentration (AUC 0-last) for Total Alectinib</title>
          <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins</description>
          <population>Pharmacokinetic population</population>
          <units>hour*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2820" spread="63.7"/>
                    <measurement group_id="O2" value="1740" spread="45.1"/>
                    <measurement group_id="O3" value="3710" spread="56.6"/>
                    <measurement group_id="O4" value="1630" spread="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>162</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>104</ci_lower_limit>
            <ci_upper_limit>254</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>228</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>129</ci_lower_limit>
            <ci_upper_limit>403</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0-last for Unbound Alectinib</title>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-last for Unbound Alectinib</title>
          <population>Pharmacokinetic population</population>
          <units>hour*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="636" spread="63.3"/>
                    <measurement group_id="O2" value="337" spread="31.9"/>
                    <measurement group_id="O3" value="699" spread="38.9"/>
                    <measurement group_id="O4" value="236" spread="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>189</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>121</ci_lower_limit>
            <ci_upper_limit>293</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>296</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>174</ci_lower_limit>
            <ci_upper_limit>506</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Total Metabolite of Alectinib (M4)</title>
        <description>Total M4 = unbound M4 plus M4 bound to plasma proteins</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Total Metabolite of Alectinib (M4)</title>
          <description>Total M4 = unbound M4 plus M4 bound to plasma proteins</description>
          <population>Pharmacokinetic population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="62.0"/>
                    <measurement group_id="O2" value="29.8" spread="89.3"/>
                    <measurement group_id="O3" value="17.5" spread="114"/>
                    <measurement group_id="O4" value="28.7" spread="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>64.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>36.2</ci_lower_limit>
            <ci_upper_limit>115</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>60.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.6</ci_lower_limit>
            <ci_upper_limit>139</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Unbound M4</title>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Unbound M4</title>
          <population>Pharmacokinetic population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="51.3"/>
                    <measurement group_id="O2" value="20.6" spread="45.4"/>
                    <measurement group_id="O3" value="8.26" spread="39.6"/>
                    <measurement group_id="O4" value="14.0" spread="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>85.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>55.5</ci_lower_limit>
            <ci_upper_limit>130</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>59.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>34.2</ci_lower_limit>
            <ci_upper_limit>102</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Total Combined Alectinib and M4 (Alectinib + M4)</title>
        <description>Total alectinib + M4 = unbound alectinib + M4 plus alectinib + M4 bound to plasma proteins</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Total Combined Alectinib and M4 (Alectinib + M4)</title>
          <description>Total alectinib + M4 = unbound alectinib + M4 plus alectinib + M4 bound to plasma proteins</description>
          <population>Pharmacokinetic population</population>
          <units>nanomoles per liter (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266" spread="23.3"/>
                    <measurement group_id="O2" value="229" spread="65.6"/>
                    <measurement group_id="O3" value="214" spread="61.3"/>
                    <measurement group_id="O4" value="218" spread="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>116</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>78.6</ci_lower_limit>
            <ci_upper_limit>172</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>98.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>51.7</ci_lower_limit>
            <ci_upper_limit>186</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Unbound Alectinib + M4</title>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Unbound Alectinib + M4</title>
          <population>Pharmacokinetic population</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" spread="24.4"/>
                    <measurement group_id="O2" value="75.9" spread="39.5"/>
                    <measurement group_id="O3" value="48.9" spread="36.1"/>
                    <measurement group_id="O4" value="50.6" spread="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>115</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.2</ci_lower_limit>
            <ci_upper_limit>154</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>96.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.6</ci_lower_limit>
            <ci_upper_limit>168</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-inf of Total M4</title>
        <description>Total M4 = unbound M4 plus M4 bound to plasma proteins. AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-inf of Total M4</title>
          <description>Total M4 = unbound M4 plus M4 bound to plasma proteins. AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
          <population>Pharmacokinetic population</population>
          <units>hour*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="583" spread="14.8"/>
                    <measurement group_id="O2" value="718" spread="70.5"/>
                    <measurement group_id="O3" value="465" spread="147"/>
                    <measurement group_id="O4" value="709" spread="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>80.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>50.2</ci_lower_limit>
            <ci_upper_limit>130</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>65.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>26.9</ci_lower_limit>
            <ci_upper_limit>160</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-inf of Unbound M4</title>
        <description>AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-inf of Unbound M4</title>
          <description>AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
          <population>Pharmacokinetic population</population>
          <units>hour*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="516" spread="27.3"/>
                    <measurement group_id="O2" value="497" spread="33.7"/>
                    <measurement group_id="O3" value="220" spread="71.1"/>
                    <measurement group_id="O4" value="345" spread="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>104</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>76.8</ci_lower_limit>
            <ci_upper_limit>141</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>63.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.0</ci_lower_limit>
            <ci_upper_limit>119</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-inf of Total Alectinib + M4</title>
        <description>Total alectinib + M4 = unbound alectinib + M4 plus alectinib + M4 bound to plasma proteins. AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-inf of Total Alectinib + M4</title>
          <description>Total alectinib + M4 = unbound alectinib + M4 plus alectinib + M4 bound to plasma proteins. AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
          <population>Pharmacokinetic population</population>
          <units>hour*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7340" spread="46.6"/>
                    <measurement group_id="O2" value="5380" spread="44.5"/>
                    <measurement group_id="O3" value="9020" spread="60.3"/>
                    <measurement group_id="O4" value="5120" spread="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>136</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.7</ci_lower_limit>
            <ci_upper_limit>196</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>176</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.4</ci_lower_limit>
            <ci_upper_limit>315</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-inf of Unbound Alectinib + M4</title>
        <description>AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-inf of Unbound Alectinib + M4</title>
          <description>AUC 0-inf = AUC from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC 0-t plus AUC t-inf.</description>
          <population>Pharmacokinetic population</population>
          <units>hour*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2420" spread="38.5"/>
                    <measurement group_id="O2" value="1800" spread="25.4"/>
                    <measurement group_id="O3" value="1960" spread="41.3"/>
                    <measurement group_id="O4" value="1250" spread="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>134</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>99.6</ci_lower_limit>
            <ci_upper_limit>181</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>157</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.8</ci_lower_limit>
            <ci_upper_limit>268</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-last of Total M4</title>
        <description>Total M4 = unbound M4 plus M4 bound to plasma proteins</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-last of Total M4</title>
          <description>Total M4 = unbound M4 plus M4 bound to plasma proteins</description>
          <population>Pharmacokinetic population</population>
          <units>hour*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475" spread="27.5"/>
                    <measurement group_id="O2" value="648" spread="79.6"/>
                    <measurement group_id="O3" value="363" spread="212"/>
                    <measurement group_id="O4" value="631" spread="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>73.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>46.2</ci_lower_limit>
            <ci_upper_limit>116</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>57.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.0</ci_lower_limit>
            <ci_upper_limit>165</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-last of Unbound M4</title>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-last of Unbound M4</title>
          <population>Pharmacokinetic population</population>
          <units>hour*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433" spread="29.6"/>
                    <measurement group_id="O2" value="448" spread="40.2"/>
                    <measurement group_id="O3" value="172" spread="100"/>
                    <measurement group_id="O4" value="308" spread="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>96.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>69.9</ci_lower_limit>
            <ci_upper_limit>134</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>55.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>26.0</ci_lower_limit>
            <ci_upper_limit>120</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-last of Total Alectinib + M4</title>
        <description>Total alectinib + M4 = unbound alectinib + M4 plus alectinib + M4 bound to plasma proteins</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-last of Total Alectinib + M4</title>
          <description>Total alectinib + M4 = unbound alectinib + M4 plus alectinib + M4 bound to plasma proteins</description>
          <population>Pharmacokinetic population</population>
          <units>hour*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7160" spread="47.6"/>
                    <measurement group_id="O2" value="5170" spread="48.2"/>
                    <measurement group_id="O3" value="8700" spread="62.7"/>
                    <measurement group_id="O4" value="4830" spread="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>139</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.8</ci_lower_limit>
            <ci_upper_limit>203</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>180</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>97.2</ci_lower_limit>
            <ci_upper_limit>334</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-last of Unbound Alectinib + M4</title>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-last of Unbound Alectinib + M4</title>
          <population>Pharmacokinetic population</population>
          <units>hour*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2390" spread="38.4"/>
                    <measurement group_id="O2" value="1750" spread="27.5"/>
                    <measurement group_id="O3" value="1890" spread="42.7"/>
                    <measurement group_id="O4" value="1200" spread="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>137</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100</ci_lower_limit>
            <ci_upper_limit>186</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Mean Ratio %</param_type>
            <param_value>158</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.2</ci_lower_limit>
            <ci_upper_limit>274</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total Alectinib</title>
        <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) for Total Alectinib</title>
          <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins</description>
          <population>Pharmacokinetic population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" lower_limit="3.82" upper_limit="23.8"/>
                    <measurement group_id="O2" value="5.97" lower_limit="3.98" upper_limit="6.10"/>
                    <measurement group_id="O3" value="7.02" lower_limit="2.00" upper_limit="11.9"/>
                    <measurement group_id="O4" value="4.97" lower_limit="3.90" upper_limit="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax for Total M4</title>
        <description>Total M4 = unbound M4 plus M4 bound to plasma proteins</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Total M4</title>
          <description>Total M4 = unbound M4 plus M4 bound to plasma proteins</description>
          <population>Pharmacokinetic population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.10" lower_limit="6.07" upper_limit="35.8"/>
                    <measurement group_id="O2" value="7.88" lower_limit="5.92" upper_limit="10.0"/>
                    <measurement group_id="O3" value="8.00" lower_limit="5.98" upper_limit="11.9"/>
                    <measurement group_id="O4" value="8.05" lower_limit="5.93" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (t1/2) of Total Alectinib</title>
        <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. t1/2 = the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) of Total Alectinib</title>
          <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. t1/2 = the time measured for the plasma concentration to decrease by one half.</description>
          <population>Pharmacokinetic population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="26.1"/>
                    <measurement group_id="O2" value="20.1" spread="21.1"/>
                    <measurement group_id="O3" value="39.3" spread="27.0"/>
                    <measurement group_id="O4" value="22.2" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2 of Total M4</title>
        <description>Total M4 = unbound M4 plus M4 bound to plasma proteins. t1/2 = the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2 of Total M4</title>
          <description>Total M4 = unbound M4 plus M4 bound to plasma proteins. t1/2 = the time measured for the plasma concentration to decrease by one half.</description>
          <population>Pharmacokinetic population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="48.0"/>
                    <measurement group_id="O2" value="19.3" spread="18.0"/>
                    <measurement group_id="O3" value="30.5" spread="68.8"/>
                    <measurement group_id="O4" value="20.1" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance (CL/F) of Total Alectinib</title>
        <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. Clearance is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) of Total Alectinib</title>
          <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. Clearance is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability.</description>
          <population>Pharmacokinetic population</population>
          <units>liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" spread="60.5"/>
                    <measurement group_id="O2" value="164" spread="40.4"/>
                    <measurement group_id="O3" value="77.9" spread="54.1"/>
                    <measurement group_id="O4" value="171" spread="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F of Unbound Alectinib</title>
        <description>Clearance is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F of Unbound Alectinib</title>
          <description>Clearance is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability.</description>
          <population>Pharmacokinetic population</population>
          <units>liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455" spread="60.5"/>
                    <measurement group_id="O2" value="845" spread="27.4"/>
                    <measurement group_id="O3" value="414" spread="37.8"/>
                    <measurement group_id="O4" value="1180" spread="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) for Total Alectinib</title>
        <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. Volume of distribution is defined as the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose is influenced by the fraction absorbed.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) for Total Alectinib</title>
          <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. Volume of distribution is defined as the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose is influenced by the fraction absorbed.</description>
          <population>Pharmacokinetic population</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3870" spread="55.7"/>
                    <measurement group_id="O2" value="4760" spread="61.3"/>
                    <measurement group_id="O3" value="4410" spread="73.0"/>
                    <measurement group_id="O4" value="5490" spread="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F for Unbound Alectinib</title>
        <description>Volume of distribution is defined as the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose is influenced by the fraction absorbed.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F for Unbound Alectinib</title>
          <description>Volume of distribution is defined as the theoretical volume which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose is influenced by the fraction absorbed.</description>
          <population>Pharmacokinetic population</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17200" spread="51.8"/>
                    <measurement group_id="O2" value="24500" spread="47.0"/>
                    <measurement group_id="O3" value="23400" spread="52.7"/>
                    <measurement group_id="O4" value="37800" spread="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Drug Unbound (fu) of Total Alectinib</title>
        <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. fu = ratio of unbound alectinib to total alectinib multiplied by 100.</description>
        <time_frame>Predose (0 hour), and at 1, 2, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose (Dosing day = Day 1)</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Alectinib: Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Alectinib: Normal Moderate Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in moderate hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Alectinib: Severe Hepatic Impairment</title>
            <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Alectinib: Normal Severe Matched Control</title>
            <description>Participants with normal hepatic function matched to the participants in severe hepatic impairment group (based on Child-Pugh score), on the basis of age, body weight and gender, received alectinib at a single oral dose of 300 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Drug Unbound (fu) of Total Alectinib</title>
          <description>Total alectinib = unbound alectinib plus alectinib bound to plasma proteins. fu = ratio of unbound alectinib to total alectinib multiplied by 100.</description>
          <population>Pharmacokinetic population</population>
          <units>percentage of total alectinib</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.225" spread="18.3"/>
                    <measurement group_id="O2" value="0.194" spread="28.4"/>
                    <measurement group_id="O3" value="0.188" spread="37.8"/>
                    <measurement group_id="O4" value="0.145" spread="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Day 21</time_frame>
      <desc>Safety population</desc>
      <group_list>
        <group group_id="E1">
          <title>Alectinib: Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 milligrams (mg) on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Alectinib: Severe Hepatic Impairment</title>
          <description>Participants with severe hepatic impairment (based on Child-Pugh score) received alectinib at a single oral dose of 300 mg on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Alectinib: Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received alectinib at a single oral dose of 300 mg on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

